Status:
UNKNOWN
Program of Evaluation and Geriatric Intervention on the Functional Status, Quality of the Life, and Survival
Lead Sponsor:
Institut Paoli-Calmettes
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
70+ years
Phase:
NA
Brief Summary
Acute myeloid leukaemia (AML) is a disease of the elderly, with a median age at diagnosis of 65. A poor outcome in this population has been well established, with very short overall survival (OS) and ...
Eligibility Criteria
Inclusion
- Patients aged 70 years and older
- Referred for treatment following a diagnosis of acute myeloid leukaemia.
- signed informed consent
Exclusion
- Terminal patients, with a life expectancy estimated to be less than 3 months, will be excluded from the study, due to ethical issues and the fact that they are unlikely to benefit from this evaluation.
- Patients unable to give informed consent.
Key Trial Info
Start Date :
March 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01188330
Start Date
March 1 2010
Last Update
October 31 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Aude CHARBONNIER, MD
Marseille, France, 13009
2
Christian RECHER
Toulouse, France